Immune checkpoint inhibitors associated inflammatory disease of central nervous system: Case report and systemic review
Open Access
- 1 August 2025
- journal article
- research article
- Published by Wolters Kluwer Health in Medicine
- Vol. 104 (31) , e43552
Abstract
Rationale: The use of immune checkpoint inhibitors (ICIs) has greatly improved the outcomes of cancer. However, ICI-induced immune-related adverse events have been reported, among which neurological immune-related adverse events are rare but potentially life-threatening. To analyze the characteristics of ICI-induced inflammatory disease of the central nervous system (CNS), we reported the first case induced by tislelizumab and conducted a systematic review of 33 cases. Patient concerns: A 65-year-old male patient who received 4 cycles of tislelizumab for lung squamous carcinoma developed myelitis, demyelinating encephalopathy, and peripheral neuropathy overlap syndrome. Case reports and case series that described ICI-associated inflammatory disease of the CNS in the PubMed and Embase databases were searched up to October 2022. Diagnoses: The patient was diagnosed with ICI-associated neuroimmune overlap syndrome, including myelitis, peripheral neuropathy, and multifocal demyelinating encephalopathy. Interventions: The patient was treated with intravenous methylprednisolone. Outcomes: The symptoms alleviated gradually. Twenty-six publications that described 33 cases with ICI-associated inflammatory disease of the CNS were reviewed. In addition to the present case, only 8 cases with both brain and spinal cord lesions induced by ICIs were reported. Intravenous steroids were the first-line therapy, while plasmapheresis, intravenous immunoglobulin, cyclophosphamide, and some monoclonal antibodies may be effective for steroid-refractory neurological immune-related adverse events. Thirteen patients experienced relapse, and 4 patients died, one of whom committed suicide. Lessons: ICI-associated inflammatory disease of the CNS is very rare, but we should be aware of and detect it to treat timely manner and achieve a good prognosis.Keywords
This publication has 41 references indexed in Scilit:
- Combination Intravenous Immune Globulin (IVIG) and High Dose Steroids for Treatment of Immune-Related Myelitis in a Non-Small Cell Lung Cancer Patient Treated With Pembrolizumab and Palliative Radiation Treatment: A Case ReportClinical Lung Cancer, 2022
- Neurological complications of cancer immunotherapyCancer Treatment Reviews, 2021
- Detect it so you can treat it: A case series and proposed checklist to detect neurotoxicity in checkpoint therapyeNeurologicalSci, 2021
- Severe anti-PD1-related meningoencephalomyelitis successfully treated with anti-integrin alpha4 therapyEuropean Journal of Cancer, 2021
- Tislelizumab: First ApprovalDrugs, 2020
- CRMP5-IgG–Associated Paraneoplastic Myelopathy With PD-L1 Inhibitor TherapyJAMA Neurology, 2020
- Seronegative antibody‐mediated neurology after immune checkpoint inhibitorsAnnals of Clinical and Translational Neurology, 2018
- Immune checkpoint inhibitor–associated CNS autoimmune disorder (ICICAD) following nivolumab treatment: A new entity of drug-induced autoimmune encephalitis?European Journal of Cancer, 2017
- Neurological adverse events associated with immune checkpoint inhibitors: Review of the literatureEuropean Journal of Cancer, 2017
- Hypophysitis Secondary to Cytotoxic T-Lymphocyte–Associated Protein 4 BlockadeThe American Journal of Pathology, 2016